Gut Bacteria Supplement Cuts Weight Regain by 60% After Dieting
A randomized trial finds pasteurized Akkermansia muciniphila nearly triples weight loss maintenance versus placebo over 24 weeks.
Riepilogo
A controlled trial of 90 overweight adults found that daily supplementation with pasteurized Akkermansia muciniphila MucT during a 24-week weight maintenance phase significantly reduced weight regain. After an initial 8-week low-energy diet, the MucT group regained only 1.2 kg versus 3.2 kg in the placebo group — a 60% reduction. Net weight loss from baseline was also greater in the MucT group (3.1 kg more than placebo). Baseline abundance of Akkermansia species in the gut predicted cardiometabolic response to treatment. No serious treatment-related adverse events occurred, suggesting this pasteurized probiotic approach is safe and may offer a practical tool for long-term weight management.
Riepilogo Dettagliato
Maintaining weight loss after dieting is one of the greatest challenges in obesity management. Most people regain significant weight within months of completing a calorie-restricted diet, and effective non-pharmacological tools for the maintenance phase are scarce. This trial investigated whether a pasteurized gut bacterium could fill that gap.
Researchers at Maastricht University enrolled 90 adults with overweight or obesity in a two-phase randomized controlled trial. All participants first underwent an 8-week low-energy diet targeting at least 8% weight loss. They were then randomized to receive either daily pasteurized Akkermansia muciniphila MucT or placebo for 24 weeks while following a healthy ad libitum diet. The primary endpoint was change in body weight during the maintenance period.
The results were striking. Participants taking MucT regained an average of only 1.2 kg over 24 weeks, compared to 3.2 kg in the placebo group — a statistically significant difference (P = 0.012). When accounting for the full trial period from baseline, the MucT group achieved 3.1 kg greater net weight loss than placebo (P = 0.009). Baseline gut abundance of Akkermansia species was associated with cardiometabolic responsiveness to supplementation, hinting at a personalized medicine angle.
These findings are notable because A. muciniphila is a naturally occurring mucosal bacterium previously shown in preclinical studies to protect against diet-induced obesity. Pasteurization retains bioactive components while improving safety and shelf stability. The absence of serious adverse events reinforces its tolerability profile.
Key limitations include the relatively short 24-week maintenance window and the lack of comparison arms using modified MucT strains that could isolate which bacterial components drive the effect. Conflicts of interest among several authors — including co-founders of The Akkermansia Company — warrant scrutiny, though the trial was independently conducted. Longer follow-up studies in diverse populations are needed.
Risultati Principali
- MucT group regained only 1.2 kg vs. 3.2 kg in placebo over 24 weeks (P = 0.012).
- Net weight loss from baseline was 3.1 kg greater in the MucT group than placebo (P = 0.009).
- Baseline gut Akkermansia abundance predicted cardiometabolic response to supplementation.
- No serious adverse events related to pasteurized A. muciniphila treatment were observed.
- Pasteurization preserves bioactive components while enhancing safety and product stability.
Metodologia
Randomized controlled trial (n = 90 overweight/obese adults) with an 8-week low-energy diet run-in phase followed by 24 weeks of daily pasteurized A. muciniphila MucT or placebo during ad libitum healthy eating. Primary outcome was body weight change during the maintenance period; registered at ClinicalTrials.gov (NCT05417360).
Limitazioni dello Studio
The 24-week maintenance window is relatively short, leaving long-term durability of the effect unknown. The trial lacked arms testing modified MucT strains, making it impossible to attribute effects to specific bacterial components. Several authors have financial ties to The Akkermansia Company, introducing potential conflict of interest.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: